CVSI (CV Sciences) EBIT per Share: $-0.01 (TTM As of Mar. 2026)


What is CV Sciences EBIT per Share?

CV Sciences CVSI -1.64% EBIT per Share is $-0.01 as of Mar. 2026. The stock has 2 warning signs investors should review. Among 811 Drug Manufacturers companies, CV Sciences ranks better than 92.48% on this metric.

CV Sciences's EBIT per Share for the three months ended in Mar. 2026 was $-0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.01.

During the past 3 years, the average EBIT per Share Growth Rate was 60.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for CV Sciences's EBIT per Share or its related term are showing as below:

CVSI' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -284.5   Med: 7.2   Max: 60.9
Current: 60.9

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of CV Sciences was 60.90% per year. The lowest was -284.50% per year. And the median was 7.20% per year.

CVSI's 3-Year EBIT Growth Rate is ranked better than
92.48% of 811 companies
in the Drug Manufacturers industry
Industry Median: 7.8 vs CVSI: 60.90

CV Sciences's EBIT for the three months ended in Mar. 2026 was $-0.55 Mil.

CV Sciences  (OTCPK:CVSI) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

CV Sciences EBIT per Share Related Terms

CV Sciences EBIT per Share Historical Data

* Premium members only.

The historical data trend for CV Sciences's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CV Sciences EBIT per Share Chart

CV Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.14 -0.05 0.02 -0.01 -0.00

CV Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 -0.00 0.00 -0.00

CV Sciences EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

CV Sciences's EBIT per Share for the fiscal year that ended in Dec. 2025 is calculated as

EBIT per Share(A: Dec. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-0.432/184.264
=-0.00

CV Sciences's EBIT per Share for the quarter that ended in Mar. 2026 is calculated as

EBIT per Share(Q: Mar. 2026 )
=EBIT/Shares Outstanding (Diluted Average)
=-0.55/186.920
=-0.00

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of $-0.01 mean?
CV Sciences (CVSI) has a EBIT per Share of $-0.01 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on CV Sciences and its competitors. According to the industry distribution chart, CV Sciences ranks #61 out of 811 companies in the Drug Manufacturers industry, placing it in the top 7.5%.
Is CV Sciences' EBIT per Share too high?
CV Sciences' current EBIT per Share is $-0.01. Based on the distribution chart, CV Sciences ranks #61 out of 811 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does CV Sciences' EBIT per Share compare to PRFX and INM?
According to the Drug Manufacturers industry distribution chart, CV Sciences ranks #61 out of 811 companies for EBIT per Share. This places CV Sciences in the top 8% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 7.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.80, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on CV Sciences and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CV Sciences's current EBIT per Share is $-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CV Sciences stock overvalued right now?
Based on GuruFocus' analysis, CV Sciences (CVSI) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.03, compared to a current price of $0.02 — trading 20% below its estimated fair value. The current EBIT per Share is $-0.01. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For CV Sciences (CVSI), the current EBIT per Share is $-0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CV Sciences Business Description

Address 9530 Padgett Street, Suite 107, San Diego, CA, USA, 92126
CV Sciences Inc is a consumer wellness company specializing in nutraceuticals and plant-based foods products. It develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol. The company sells its products under tradenames, such as +PlusCBD, PlusCBD Pet, PlusHLTH, Cultured Foods, and Lunar Fox. The company's products are sold in a variety of market sectors, including nutraceutical, beauty care, and specialty foods. The company has one operating segment, which is the business of hemp-based CBD wellness products. Geographically, all of the company's revenue is generated from United States. The company also operates a drug development program focused on developing and commercializing CBD-based novel therapeutics.